NLS Pharmaceutics Merger Vote Scheduled
Ticker: NCEL · Form: 6-K · Filed: Jan 16, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 16, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, shareholder-meeting, corporate-action
Related Tickers: NLS
TL;DR
NLS merger vote is happening, shareholders to decide fate.
AI Summary
On January 16, 2025, NLS Pharmaceutics Ltd. announced that Kadimastem has called for a Special General Meeting of Shareholders to approve a merger with NLS. This press release, furnished as Exhibit 99.1, is incorporated by reference into NLS Pharmaceutics' existing F-3 registration statements.
Why It Matters
This filing indicates a significant step towards a potential merger, which could reshape NLS Pharmaceutics' corporate structure and future operations.
Risk Assessment
Risk Level: medium — Mergers are complex and subject to shareholder approval and regulatory hurdles, introducing uncertainty.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Kadimastem (company) — Company calling for shareholder meeting
- January 16, 2025 (date) — Date of press release
FAQ
What is the purpose of the Special General Meeting of Shareholders called by Kadimastem?
The Special General Meeting of Shareholders has been called to approve the merger with NLS Pharmaceutics Ltd.
What is the filing date of this Form 6-K?
This Form 6-K was filed on January 16, 2025.
Which exhibit is being furnished with this report?
Exhibit 99.1, a press release titled 'Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS.', is being furnished.
What type of company is NLS Pharmaceutics Ltd.?
NLS Pharmaceutics Ltd. is a foreign private issuer.
Into which of NLS Pharmaceutics' filings is the press release incorporated by reference?
The press release is incorporated by reference into NLS Pharmaceutics' Registration Statements on Form F-3 (File Nos. 333-282788, 333-262489, 333-268690 and 333).
Filing Stats: 279 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2025-01-16 09:20:34
Filing Documents
- ea0227886-6k_nlsphar.htm (6-K) — 10KB
- ea022788601ex99-1_nlsphar.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 60KB
- 0001213900-25-004027.txt ( ) — 112KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 16, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2